26 results on '"Campone M"'
Search Results
2. Prospective evaluation of serum anti-Müllerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancer
3. Array CGH and PIK3CA/AKT1 mutations to drive patients to specific targeted agents: A clinical experience in 108 patients with metastatic breast cancer
4. Multicentre phase II and pharmacokinetic study of RFS2000 (9-nitro-camptothecin) administered orally 5 days a week in patients with glioblastoma multiforme
5. Outcomes of 9800 metastatic luminal HER2-negative breast cancer patients in the French national real-life UNICANCER ESME-breast cohort
6. Efficacy and safety of ribociclib (LEE011) + letrozole in elderly patients with hormone receptor-positive (HR+), HER2-negative (HER2−) advanced breast cancer (ABC) in MONALEESA-2
7. Ribociclib + letrozole for first-line treatment of HR+, HER2− ABC: efficacy, safety, and pharmacokinetics
8. 102 (PB-003) - Outcomes of 9800 metastatic luminal HER2-negative breast cancer patients in the French national real-life UNICANCER ESME-breast cohort
9. 1865 Activity and toxicity profile of eribulin mesylate in heavily pretreated metastatic breast cancer: An observational study (EVHALAVEN)
10. 1874 Phase 1b/2 study results for masitinib plus gemcitabine and carboplatin in advanced triple negative breast cancer
11. 1320 Eribulin mesylate in metastatic breast cancer, a focus on safety and efficacy in elderly patients. Results from the EVHALAVEN multicentric retrospective cohort
12. 2LBA - Efficacy and safety of ribociclib (LEE011) + letrozole in elderly patients with hormone receptor-positive (HR+), HER2-negative (HER2−) advanced breast cancer (ABC) in MONALEESA-2
13. 431 Real-time pharmacokinetic (PK) results from an ongoing randomized, parallel-dose phase 1 study of onapristone in patients (pts) with progesterone receptor (PR)-expressing cancers
14. 586 Phase I study of pan-histone deacetylase inhibitor abexinostat in combination with cisplatin in patients with advanced solid tumors
15. 500 Triple blockade with LEE011, everolimus, and exemestane in women with ER+/HER2− advanced/metastatic breast cancer: results from a Phase Ib clinical trial
16. 1LBA Everolimus plus exemestane for hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2–) advanced breast cancer (BC): overall survival results from BOLERO-2
17. 12LBA - Ribociclib + letrozole for first-line treatment of HR+, HER2− ABC: efficacy, safety, and pharmacokinetics
18. SP006 Rationale of the design of the SHIVA trial
19. 353 Assessment of Circulating Tumor Cells and Serum Markers for Progression-free Survival Prediction in Metastatic Breast Cancer: a Prospective Observational Study
20. 5021 POSTER DISCUSSION Multivariable Prognostic Model for Individual Survival Prediction of Metastatic Breast Cancer Patients Taking Into Account Circulating Tumour Cells (CTC) Count Before and During Chemotherapy
21. 248 INVITED How to Reverse the Resistance to Trastuzumab
22. Everolimus in Combination with Exemestane for Postmenopausal Women with Advanced Breast Cancer Who Are Refractory to Letrozole or Anastrozole: Results of the BOLERO-2 Phase III Trial
23. 5023 POSTER DISCUSSION Cyfra 21-1 Correlation With Circulating Tumour Cells (CTC) Detection and Patient Outcome in Metastatic Breast Cancer: Results of a Substudy of the Prospective IC 2004-06 Trial
24. A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: A phase I/II study
25. Trends in G-CSF use in 990 patients after EORTC and ASCO guidelines
26. Evaluation of the safety of C-1311 (SYMADEX) administered in a phase 1 dose escalation trial as a weekly infusion for 3 consecutive weeks in patients with advanced solid tumours
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.